Milei Threatens Falkland Oil Firms With Sanctions 
France Targets Shein, Temu With Fast-Fashion Fees 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
EMERYVILLE, Calif., March 06, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 3:30 p.m. ET
- Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 9:00 a.m. ET
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
About Adamas Pharmaceuticals, Inc.
Adamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease, with a pipeline of differentiated investigational programs, which includes: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]
Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
